Treatments

*August 2024* Highlights •TKI have revolutionized the course of advanced NSCLC with EGFR common mutation. •Tumor heterogeneity and acquired resistance mechanisms are unavoidable limits. •Multiple novel treatment strategies based on various combinations have emerged. •Treatment strategy should be based on the clinical and biological profile. •Taking patients preferences into account is…

*July 2024* Health Canada has approved osimertinib (Tagrisso) in combination with pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R mutations.1 The regulatory decision was supported by data from the phase 3…

*June 2024* Drs. Benjamin Levy, Antoinette (Toni) Wozniak, and Isabel Preeshagul discussed the news from this year’s ASCO Annual Meeting – a premier scientific event for oncology professionals, patient advocates, industry representatives, and the media. ASCO, or American Society of Clinical Oncology, is a leading organization for health care professionals…

*August 2024* Treatment with LP-300 in combination with pemetrexed (Alimta) and carboplatin led to disease control and may elicit durable responses in never-smokers with advanced non–small cell lung cancer (NSCLC) who have progressed following prior treatment with a TKI, according to preliminary findings from the phase 2 HARMONIC trial (NCT05456256).1…

*June 2024* The FDA has issued a complete response letter (CRL) to the biologics license application (BLA) seeking the approval of patritumab deruxtecan (HER3-DXd) for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR mutations who previously received with 2 or more systemic therapies.1…

*June 2024* Highlights Largest dataset of NSCLC with uncommon EGFR alterations treated with osimertinib. Best outcomes with compound uncommon–common EGFR mutations and with G719X, L861X, or S768I. Heterogeneous activity with rarer mutations; no response with alterations at E709 residue. Confirmed activity in the central nervous system, with intracranial ORR of 58%. Amplification of EGFR or MET, TP53 mutations, and EGFR E709K…

*June 2024* Highlights The FDA has received a biologics license application (BLA) submission for amivantamab-vmjw (Rybrevant) and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab). The submission is for all currently approved or submitted indications of intravenous amivantamab in select patients with non–small cell lung cancer (NSCLC). Data from the…

*July 2024* Highlights •Addition of pemetrexed-platinum on first-line osimertinib progression is effective. •Patients with L858R and baseline CNS metastases also benefit from this approach. •Early initiation of chemotherapy after osimertinib failure improves outcomes. Abstract Objectives First-line pemetrexed-platinum chemotherapy + osimertinib(Pem-Plat-Osi) improves progression-free survival as compared to osimertinib alone in advanced epidermal growth…

*June 2024* Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study. Findings of a second interim analysis of overall safety (OS) showed encouraging trends for osimertinib (Tagrisso) and platinum-pemetrexed chemotherapy over osimertinib monotherapy in patients…

Key Takeaways: -Osimertinib significantly improved PFS in unresectable, stage III NSCLC with EGFR mutations post-chemoradiotherapy. -Median PFS was 39.1 months for osimertinib versus 5.6 months for placebo. -Objective response rate and disease control rate were higher with osimertinib. -Safety profile showed higher rates of adverse events in the osimertinib arm,…